United States: AbbVie (ABBV.N) secured U.S. Food and Drug Administration approval for its Emblaveo drug to treat complex intra-abdominal infections accompanied by drug-resistant bacteria.
New Treatment’s Potential
Emblaveo from AbbVie, along with Pfizer (PFE.N), receives approval from the FDA for treating complicated intra-abdominal infections in people aged 18 and above who need combination antibiotic treatment, as reported by Reuters.
The number of people dying from antibiotic-resistant bacteria has increased worldwide leading health regulators to demand alternative anti-bacterial treatments because resistances against traditional antibiotics continue to spread.
Understanding IAIs
The abdominal cavity serves as the location where intra-abdominal infections (IAIs) form as a collective type of infection. These conditions include simple appendicitis and severe conditions that begin as pancreatic infections.
The yearly prevalence of IAIs affects 3.5 million individuals in the United States while causing abdominal discomfort and fever along with nausea and vomiting symptoms.
AbbVie states Emblaveo effectively treats IAIs alongside infections caused by Gram-negative bacteria that possess elevated antimicrobial medicine resistance.
How Emblaveo Fights Resistant Infections
Approval came from testing Emblaveo on 422 patients to reach the primary success threshold of complete infection symptom elimination, as reported by Reuters.
Emblaveo received European authorization in April of last year while its U.S. launch is scheduled for the third quarter of 2025.
The U.S. and Canada commercial rights for Emblaveo therapy belong to AbbVie while the pharmaceutical company Pfizer maintains commercial rights for the rest of the world.